2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH DENA BATTLE
Patient Perspectives on Cytoreductive Nephrectomy after the CARMENA Trial

VIEW ALL ASCO GU 2019 VIDEOS

Prostate Cancer Foundation 2018 Scientific Retreat

Prostate Cancer Foundation 2018 Scientific Retreat

INTERVIEW WITH OLIVER SARTOR
Overall Survival Benefit and Racial Disparities in African American Men with Metastatic Prostate Cancer

VIEW ALL PCF VIDEOS

2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH KARIM FIZAZI
ARAMIS - Efficacy and Safety of Darolutamide in nmCRPC

VIEW ALL ASCO GU 2019 VIDEOS

2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH JAMES GULLEY
Immunotherapy Across Genitourinary Malignancies

VIEW ALL ASCO GU 2019 VIDEOS

Featured Videos

#AUA14 - Neoadjuvant approaches for high-risk prostate cancer - Session Highlights

ORLANDO, FL USA (UroToday.com) - The rationale for neoadjuvant therapy (NAT) in high-risk prostate cancer (HRPC) is the same as the rationale for any disease for which NAT is used, to optimize local control and treat micrometastases. Androgen deprivation therapy (ADT) in conjunction with radiation improves overall and cancer-specific surgery, so a precedence has been set for prostate cancer patients. However, there is no biological rationale for synergy between ADT and surgery like there is for ADT and radiation.

auaHe then went on to show that NAT with ADT has been tried before but has not really resulted in positive outcomes in terms of long-term cancer control, although some near-term outcomes, such as downstaging, may have occurred. He posited that the lack of positive findings might be due to lack of complete AR blockade based on tissue androgen levels and showed data supporting this idea from clinical samples from patients treated with ADT as a NAT. The Taplin neoadjuvant abiraterone study has so far shown the lowest tissue androgen level, but as Dr. Montgomery pointed out, the level is still high enough to activate AR.

He ended by suggesting that combination of ADT and other targeted therapy might provide the basis of further studies. He listed such trials including the PUNCH trial and enzalutamide/abiraterone combination NAT.

Presented by Robert Bruce Montgomery, MD at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

Seattle Cancer Care Alliance, Seattle, WA USA

Written by Phillip Abbosh, MD, PhD, medical writer for UroToday.com

 

Conference Coverage
 
Recent data from conferences worldwide
Journals
Publications focusing on urologic cancer treatments through original manuscripts
Everyday Urology Volume 3 Issue 4

Everyday Urology™ - Oncology Insights

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe